Clinical Trial Update: Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Everolimus with reduced cyclosporine versus mycophenolic acid with cyclosporine in kidney transplant recipients; the study is completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection
• Kidney Transplantation

Drugs mentioned

• Everolimus (everolimus)
• Mycophenolic acid (mycophenolic acid)

Snippet

Sponsor: Novartis | Conditions: Kidney Transplantation, Graft Rejection | Phase 3 | Status: COMPLETED | Results posted: 2011-05-10